Drug Pipeline

In developing its pipeline of cancer therapeutics, Deciphera has applied the distinct capabilities of its kinase inhibitor platform with a strategic focus by:

  • developing advanced Type 2 kinase inhibitors with demonstrated activity against many of the most clinically important kinase targets in oncology today, such as MET, TIE2, VEGFR1, VEGFR2, RAF, KIT and FMS;
  • targeting kinases that play important roles in tumor communication with the surrounding tissue, known as the tumor microenvironment.

Deciphera’s pipeline of clinical candidates , includes Rebastinib, a TIE2 kinase inhibitor for the adjuvant treatment of solid tumors including pancreatic and breast cancers, and DCC-2701, a MET/TIE2/VEGFR2 kinase inhibitor for the treatment of metastatic melanoma and other invasive solid tumors. Preclinical pipeline assets include DP-4978, a pan-RAF inhibitor developed in collaboration with Eli Lilly, DCC-2618, a pan-KIT inhibitor for GIST, mast cell cancers, and other KIT-driven cancers, DCC-3014, an ultra-selective FMS inhibitor for the adjuvant treatment of solid tumor metastasis and for blocking cancer spread to bones., and DCC-2721, a selective MET inhibitor for the treatment of invasive solid tumors including gastric cancer.

Term ID: 3

Targeted kinases:
Tumor Cell: (TRK, BCR-ABL) Tumor Microenvironment: (TIE2)
Targeted cancers:
breast, hepatocellular carcinoma, glioblastoma, papillary thyroid cancer, melanoma, ovarian, renal, colon, CML
Dose Form:
Targeted kinases:
Tumor Cell: (cMET) Tumor Microenvironment: (TIE2, VEGFR2, cMET)
Targeted cancers:
solid tumors and highly invasive metastatic cancers
Dose Form:

Term ID: 2

Targeted kinases:
B-RAF, C-RAF, A-RAF
Targeted cancers:
melanoma, colorectal cancer, Ras-driven cancers
Dose Form:
Targeted kinases:
FMS, expressed both in tumor cells and in cells of the tumor microenvironment
Targeted cancers:
osteolytic cancers, gliomas, breast cancer, renal cell carcinoma, tumor and bone metastases
Dose Form:
Targeted kinases:
cMET
Targeted cancers:
solid tumors and highly invasive metastatic cancers
Dose Form:
Targeted kinases:
mutant cKIT (including exons 14 and 17) and mutant PDGFRα
Targeted cancers:
gastrointestinal stromal tumors (GIST), mast cell leukemia, mastocytosis
Dose Form: